Table 3.
Predictors of sustained viral load suppression among people living with human immunodeficiency virus in Rwanda
|
Characteristics
|
Complete case analysis
|
Imputed datasets
|
||||||
| Bivariate | Multivariable | Bivariate | Multivariable | |||||
|
IRR (95%CI)
|
P value
|
aIRR (95%CI)
|
P value
|
IRR (95%CI)
|
P value
|
aIRR (95%CI)
|
P value
|
|
| Age, year | ||||||||
| 18-24 | Reference | - | Reference | - | Reference | - | Reference | - |
| 25-34 | 1.10 (0.86-1.40) | 0.455 | 0.99 (0.83-1.19) | 0.944 | 1.10 (0.86-1.40) | 0.455 | 1.09 (0.87-1.35) | 0.484 |
| 35-44 | 1.03 (0.81-1.32) | 0.792 | 0.94 (0.78-1.14) | 0.540 | 1.03 (0.81-1.32) | 0.792 | 1.03 (0.83-1.29) | 0.776 |
| 45-54 | 1.20 (0.94-1.52) | 0.148 | 1.12 (0.92-1.35) | 0.251 | 1.20 (0.94-1.52) | 0.148 | 1.22 (0.97-1.52) | 0.086 |
| ≥ 55 | 1.05 (0.81-1.37) | 0.691 | 0.98 (0.80-1.22) | 0.879 | 1.05 (0.81-1.37) | 0.691 | 1.09 (0.85-1.36) | 0.492 |
| Gender | ||||||||
| Female | Reference | - | Reference | - | Reference | - | Reference | - |
| Male | 0.95 (0.89-1.02) | 0.139 | 0.96 (0.89-1.03) | 0.230 | 0.95 (0.89-1.02) | 0.139 | 0.95 (0.89-1.02) | 0.136 |
| Education | ||||||||
| No education | Reference | - | Reference | - | Reference | - | Reference | - |
| ≥ Primary | 1.08 (1.01-1.16) | 0.012a | 1.09 (1.01-1.17) | 0.031a | 1.09 (1.02-1.16) | 0.012a | 1.09 (1.02-1.16) | 0.012a |
| HIV status disclosed | ||||||||
| No | Reference | - | Reference | - | Reference | - | Reference | - |
| Yes | 0.99 (0.93-1.05) | 0.733 | 1.00 (0.94-1.09) | 0.840 | 0.99 (0.93-1.05) | 0.771 | 1.00 (0.94-1.06) | 0.952 |
| Adherence | ||||||||
| < 90% | Reference | - | Reference | - | Reference | - | Reference | - |
| ≥ 90% | 1.09 (1.00-1.20) | 0.050a | 1.05 (0.96-1.15) | 0.309 | 1.06 (0.99-1.15) | 0.111 | 1.04 (0.96-1.12) | 0.349 |
| Advance HIV disease | ||||||||
| No | Reference | - | Reference | - | Reference | - | Reference | - |
| Yes | 0.87 (0.78-0.97) | 0.014a | 0.88 (0.79-0.99) | 0.034a | 0.89 (0.81-0.98) | 0.020a | 0.89 (0.82-0.98) | 0.019a |
| Timing of ART initiation | ||||||||
| Before treat all | Reference | - | Reference | - | Reference | - | Reference | - |
| After treat all | 0.98 (0.92-1.04) | 0.543 | 0.97 (0.90-1.05) | 0.466 | 0.97 (0.92-1.04) | 0.432 | 0.97 (0.91-1.04) | 0.385 |
P < 0.05, indicates statistically significant results.
HIV: Human immunodeficiency virus; ART: Antiretroviral therapy; IRR: Incidence risk ratio; aIRR: Adjusted incidence risk ratio; CI: Confidence interval.